Asia-Pacific Computed Tomography (CT) Market Size

Asia Pacific Computed Tomography (CT) Market Analysis

The Asia-Pacific Computed Tomography Market size is estimated at USD 2.66 billion in 2024, and is expected to reach USD 3.62 billion by 2029, growing at a CAGR of 6.46% during the forecast period (2024-2029).

COVID-19 significantly impacted the computed tomography market due to the cancelations of elective procedures, including diagnostic imaging, in the initial phases. The CT examination played an important auxiliary role in diagnosing and managing COVID-19 patients. These findings increased the demand for CT scans in the country during the later phase of COVID-19. For instance, according to a research article published in Medicine Journal in September 2021, CT is a sensitive tool for diagnosing symptomatic COVID-19 patients. Among the 1,014 hospitalized patients with obvious symptoms from Wuhan, China, the CT scans of most patients were abnormal.

Therefore, CT was used as an auxiliary assessment tool for children and adults with COVID-19. The demand for CT scanners paced up since the restrictions were lifted and diagnostic laboratories resumed their services. The impact of COVID-19 on the studied market has seized in the current scenario due to the significant reduction in cases. Moreover, the market is expected to register a stable growth rate during the forecast period.

The increasing adoption of minimally invasive surgical (MIS) and non-invasive procedures among the Australian population is also contributing to the growth of the studied market. For instance, an article published in a British medical journal in April 2022 stated that the use of CT scans has increased significantly to 14,506 per 100,000 person-years in recent years in Australia. Thus, the large number of CT scan procedures in the country for diagnostics is expected to propel the growth of the studied market.

Additionally, the region's high burden of chronic diseases such as cardiovascular and respiratory disorders is expected to fuel the demand for CT for efficient and early diagnosis of such diseases. For instance, according to the Australian Bureau of Statistics, March 2022 update, the prevalence of heart disease in Australia was 4.0%, which represented 1.0 million people in 2021. Heart disease increased with age, from 2.3% of people aged 45-54 to 23.2% of those aged 75 years and over. The same source stated that in 2021, around 375.8 thousand individuals (1.5%) of all ages had chronic obstructive pulmonary disease (COPD). The country's high burden of cardiovascular diseases and COPD is projected to boost the demand for computed tomography diagnosis for managing these diseases, which is likely to augment market growth.

Furthermore, the strategic initiatives by market players, such as product launches, approvals, and partnerships, are also contributing to market growth. For instance, in April 2022, Wipro GE Healthcare launched its next-generation Revolution Aspire CT scanner. Revolution Aspire is designed and manufactured in India at the newly launched Wipro GE Medical Devices Manufacturing plant, in line with the 'Atmanirbhar Bharat' initiative.

Therefore, owing to the aforementioned factors, such as the high burden of cardiovascular and respiratory diseases leading to large adoption of CT procedures and rising launches by market players, the studied market is anticipated to witness growth over the analysis period. However, the lack of adequate reimbursement and stringent regulatory framework is likely to impede market growth.